Mette Gyldenløve

MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis

Marianne Bengtson Løvendorf, John R. Zibert, Mette Gyldenløve et al. · Journal of Dermatological Science · 2014 · 101 citations

Medicine, Dermatology, Molecular Biology +14

Patients with psoriasis are insulin resistant

Mette Gyldenløve, Heidi Storgaard, Jens J. Holst et al. · Journal of the American Academy of Dermatology · 2015 · 91 citations

Medicine, Dermatology, Endocrinology +8

Lack of effect of the glucagon‐like peptide‐1 receptor agonist liraglutide on psoriasis in glucose‐tolerant patients – a randomized placebo‐controlled trial

Annesofie Faurschou, Mette Gyldenløve, Ulrich Rohde et al. · Journal of the European Academy of Dermatology and Venereology · 2014 · 86 citations

Medicine, Dermatology, Pharmacology +17

Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO)

Mette Gyldenløve, Howraman Meteran, Jennifer Astrup Sørensen et al. · The Lancet Regional Health - Europe · 2023 · 41 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects

Mia Demant, Jonatan I. Bagger, Malte P. Suppli et al. · Metabolic Syndrome and Related Disorders · 2018 · 37 citations

Medicine, Endocrinology, Physiology +12